By investigator assessment, NIVO + Chemo showed PFS benefit versus Chemo in patients with tumor-cell PD-L1 ≥ 1% (8.0 vs. 3.0 months; HR, 0.36 [0.23–0.56]) and in all randomized patients (6.8 vs. 4.2 months; HR 0.58 [0.44–0.76]) (Online Resource 4). This evidence concerns the gene CD274 and neoplasm.